1-6 of 6
Rahul Karnik
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors

Tatyana Feldman, Enrica Marchi, Stephen D. Smith, Adam J. Olszewski, Auris O Huen, Zachary D. Epstein-Peterson, Don A. Stevens, Alexander N. Starodub, Eric J. Feldman, Cristina P Rodriguez, John C. Reneau, Jonathan E. Brammer, Ahmad H. Mattour, Lauren C. Pinter-Brown, Rachelle Perea, Patrick Henrick, Joyoti Dey, Alyssa Fasciano, Rahul Karnik, Sagar Agarwal, Ashwin Gollerkeri, Jared Gollob, Aditi Shastri, Stefan K. Barta
Journal: Blood
Blood (2024) 144 (Supplement 1): 4433.
https://doi.org/10.1182/blood-2024-210301
Published: 2024
Journal Articles

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Aditi Shastri, Eric J Feldman, Alexander N Starodub, Tatyana Feldman, Cristina P Rodriguez, Zachary D. Epstein-Peterson, Don A. Stevens, Adam J Olszewski, Auris O Huen, Pierluigi Porcu, John C Reneau, Stefan K. Barta, Enrica Marchi, Ahmad H Mattour, Lauren C. Pinter-Brown, Rachelle Perea, Sean Donohue, Joyoti Dey, Sagar Agarwal, Rahul Karnik, Ashwin Gollerkeri, Jared Gollob, Stephen D Smith
Journal: Blood
Blood (2023) 142 (Supplement 1): 3081.
https://doi.org/10.1182/blood-2023-181130
Published: 2023
Journal Articles

Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

Michele Mayo, Yogesh Chutake, Rahul Karnik, Alice McDonald, Patricia S. Cho, Jessica Filiatrault, Dapeng Chen, Vaishali Dixit, William Proctor, Susanne Breitkopf, Frank Qi, Kan-Nian Hu, Kirti Sharma, Reggie Ewesuedo, Matt Weiss, Joseph D. Growney, Juliet Williams, Stefanie S Schalm
Journal: Blood
Blood (2022) 140 (Supplement 1): 6239–6240.
https://doi.org/10.1182/blood-2022-169021
Published: 2022
Journal Articles

A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers

Phillip CC Liu, Vaishali Dixit, Michele Mayo, Joyoti Dey, Karen Yuan, Rahul Karnik, Dirk Walther, Yatao Shi, Kirti Sharma, Haojing Rong, Bin Yang, Ashwin Gollerkeri, Jared Gollob, Chris DeSavi
Journal: Blood
Blood (2021) 138 (Supplement 1): 1865.
https://doi.org/10.1182/blood-2021-151125
Published: 2021
Journal Articles

Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens

Giuseppina Astone, Luca Vincenzo Cappelli, William Chiu, Clarisse Kayembe, Rui Wang, Bin Yang, Kirti Sharma, Joyoti Dey, Rahul Karnik, Lara Brambilla, David Levy, Liron Yoffe, Francesco Boccalatte, Javier Rodriguez Hernaez, Aristotelis Tsirigos, Paul Zumbo, Doron Betel, Akanksha Verma, Olivier Elemento, Michela Cumerlato, Roberto Piva, Steven M. Horwitz, Zachary D. Epstein-Peterson, Jared Gollob, Chris DeSavi, Phillip CC Liu, Giorgio Inghirami
Journal: Blood
Blood (2021) 138 (Supplement 1): 865.
https://doi.org/10.1182/blood-2021-153995
Published: 2021
Journal Articles

Mechanisms of the Anti-Tumor Activity of STAT3 Degraders in Lymphoma

Haojing Rong, PhD, Kirti Sharma, Fred Csibi, Bin Yang, Scott Rusin, Yatao Shi, PhD, Joyoti Dey, PhD, Rahul Karnik, Michele Mayo, Karen Yuan, Yogesh Chutake, Alice McDonald, PhD, Sean Zhu, PhD, Nan Ji, PhD, Phillip Liu, PhD, Henry Li, PhD, Duncan Walker, PhD, Jared Gollob, PhD MD, Nello Mainolfi, PhD, Chris Desavi
Journal: Blood
Blood (2020) 136 (Supplement 1): 42.
https://doi.org/10.1182/blood-2020-137778
Published: 2020